Swedish Orphan Biovitrum (STO: SOBI) and US biotech major Biogen (NASDAQ: BIIB) have received European approval for their Alprolix (rFIXFc) extended half-life therapy for hemophilia B.
The European Commission (EC) gave the green light to the treatment and also maintained its orphan designation.
Alprolix is the only recombinant factor IX Fc fusion protein therapy for hemophilia B to offer people in the European Union prolonged protection against bleeding episodes with fewer prophylactic injections.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze